AMINOHIPPURIC ACID, OMNIPAQUE 300 mg I/ml soluzione iniettabile, Felzartamab clinical trials

Rescue Therapy with the Human Anti-CD38 Antibody MOR202 (felzartamab) in Patients with Membranous Nephropathy who Failed Anti-CD20 Target Therapy (MONET study)

This study looks at a new medicine called felzartamab for people with a kidney condition called membranous nephropathy, who haven't improved with other treatments. It aims to see if the new medicine can reduce protein in their urine and help their kidneys get better.